Peptide Schedule
Neuropeptide Y (NPY)36 residuesYPSKPDNPGEDAPAEDMARYYSALRHYINLITRQRYEach bubble = one amino acid. Size = residue mass. Color = chemical class.Neuropeptide Y (NPY) Dosage Calculator
Neuropeptide Y (NPY) is a highly conserved 36-amino-acid peptide belonging to the pancreatic polypeptide family, which also includes peptide YY (PYY) and pancreatic polypeptide (PP).
50mcg · Daily
Summary: Add 2mL BAC water to your 1mg vial. Draw to 10.0 units on a U-100 syringe for a 50mcg dose. This vial will last 20 doses.
Cycle Planner
Neuropeptide Y (NPY) Pharmacokinetics
Pharmacokinetics — Active Dose Over Time
t½ = ~20-30 minutes (plasma)Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.
Neuropeptide Y (NPY) Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 50mcg | Daily |
| Moderate | 100mcg | Daily |
| Aggressive | 200mcg | 2x Daily |
Note: Neuropeptide Y is a 36-amino-acid peptide and one of the most abundant neuropeptides in the mammalian central and peripheral nervous systems. It acts through a family of G-protein-coupled receptors designated Y1 through Y5, each mediating distinct physiological effects. NPY is the most potent orexigenic (appetite-stimulating) peptide identified in the brain, with intracerebroventricular administration producing marked feeding behavior in animal models. Beyond appetite regulation, NPY modulates stress and anxiety responses, vasoconstriction, circadian rhythm entrainment, bone homeostasis, and immune function. Research use requires careful handling due to its short plasma half-life and the complexity of its receptor subtypes. Exogenous NPY administration remains strictly investigational, and all work should be conducted under appropriate research protocols with institutional oversight.
About Neuropeptide Y (NPY)
Neuropeptide Y (NPY) is a highly conserved 36-amino-acid peptide belonging to the pancreatic polypeptide family, which also includes peptide YY (PYY) and pancreatic polypeptide (PP). First isolated from porcine brain in 1982 by Tatemoto and colleagues, NPY is one of the most abundant and widely distributed neuropeptides in both the central and peripheral nervous systems. It is synthesized primarily in the arcuate nucleus of the hypothalamus, the brainstem, and sympathetic neurons throughout the body. NPY exerts its biological effects through five known G-protein-coupled receptor subtypes: Y1, Y2, Y4, Y5, and the less characterized Y6. The Y1 and Y5 receptors are most closely associated with orexigenic (appetite-stimulating) signaling, while Y2 receptors function as presynaptic autoreceptors that modulate NPY release. The Y4 receptor preferentially binds pancreatic polypeptide but retains affinity for NPY. This receptor diversity allows NPY to participate in a remarkably broad range of physiological processes. In the hypothalamus, NPY is the most potent known stimulator of food intake. Central administration of NPY in rodent models triggers immediate and dose-dependent feeding, and chronic infusion produces sustained hyperphagia, weight gain, and metabolic shifts toward lipogenesis. NPY levels rise during fasting and caloric restriction, acting as a key hunger signal that integrates energy homeostasis with behavioral output. Beyond metabolism, NPY plays critical roles in the stress response. It is co-released with norepinephrine from sympathetic nerve terminals and acts as an anxiolytic agent in the amygdala and hippocampus. High NPY levels are associated with stress resilience, and studies in military personnel have correlated elevated plasma NPY with improved performance under extreme stress. NPY also contributes to cardiovascular regulation through potent vasoconstriction, modulates circadian rhythms via the suprachiasmatic nucleus, and influences bone remodeling through Y1 and Y2 receptor signaling in osteoblasts. As an exogenous research compound, NPY remains investigational with no approved therapeutic indications.